Israeli technology company New Phase has announced that it has secured FDA approval to commence clinical trials of its technology aimed at transforming late-stage cancer from a terminal illness to a chronic condition. The breakthrough technology promises to extend life expectancy and manage disease symptoms without the common side effects associated with current treatment options.
In the future, New Phase’s innovative treatment has the potential to revolutionize advanced cancer treatment, making it comparable to HIV treatment. By stabilizing the disease, prolonging patient lifespan, and improving quality of life while reducing symptoms and avoiding the debilitating side effects of aggressive therapies currently in use.
The Sarah Nanotechnology System, developed by New Phase, is a patented system that utilizes precision targeting to differentiate between cancerous and healthy cells. This enables selective destruction of only cancerous cells, minimizing damage to healthy cells. The system employs nanoparticle delivery that accumulates at tumor sites after intravenous injection followed by exposure to magnetic fields that heat and destroy cancer cells with temperature control capabilities. This systemic approach addresses micrometastases and multiple tumors in late-stage cancer.
Following successful clinical trials at Israel’s Rabin Medical Center treating patients with lung, colon, cervical, and liver cancer, New Phase plans to initiate trials in a U.S hospital by 2026 with an aim of bringing the treatment to market by 2027. Co-founded by Ofer Shalev and Dr. Rafi Hof, New Phase pays tribute to Dr. Hof’s late mother with its technology based near the Rabin Medical Center in Israel. The company has raised $34 million from Israeli, American
